Intelligent BIO Solutions Inc. is a US-listed company in the health care equipment industry. Its financial year ends in June.
Loading chart…
Third-party market data · may be delayed
~$1.4
Price-to-sales vs peers
Base case. Range ~$1.4–$7.2. Sales per share times peers' typical price-to-sales; used only when earnings are negative.
No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.
Intelligent BIO Solutions Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Intelligent BIO Solutions has little or no product revenue yet. It passes 2 of our 3 financial-health checks. Our price-to-sales vs peers value is $2.58 a share.
Source: 10-K/A filed October 21, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Intelligent BIO Solutions Inc.'s trailing-twelve-month revenue grew 38.1% year on year, with a free-cash-flow margin of -285.9%. Where it stands out: change in growth rate of +22.9pp ranks 7 of 129 health care equipment companies we cover. Where it lags: free-cash-flow margin of -285.9% ranks 112 of 128 health care equipment companies we cover.
Current signal Net margin expanding: TTM net margin reached -294.9%, up 51.3pp year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
We value Intelligent BIO Solutions Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.17 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$1.4 ~$1.7–$7.2 | Included, half weight |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$1.4 ~$1.4–$7.2 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Intelligent BIO Solutions Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Share price | $9456.00 | $1588.80 | $333.60 | $19.20 | $17.20 | $2.29 |
| Market value | $2.7bn | $647m | $186m | $10m | $9m | $3m |
| + Net debt (− = net cash) | −$13m | −$8m | −$781171 | −$6m | −$822763 | −$4m |
| Enterprise value | $2.7bn | $639m | $185m | $5m | $8m | −$612365 |
| Multiples | ||||||
| Price / sales | n/m | n/m | 148.1x | 3.3x | 3.0x | 0.8x |
| Price / earnings | — | — | — | — | — | — |
| Price / free cash flow | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$5.18 | +39% | $6m | +45% |
| Next | −$4.06 | +22% | $9m | +44% |
In the last 30 days, 0 analysts raised Intelligent BIO Solutions Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 60 days ago | −$5.18 | −$4.06 |
| 30 days ago | −$5.18 | −$4.06 |
| 7 days ago | −$5.18 | −$4.06 |
| Now | −$5.18 | −$4.06 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$1.58 | −$0.90 | +43.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| INBS | −81% | −86% | −92% | −66% | −32% | −83% |
| Industry peers (median) | −7% | −37% | −8% | −19% | −16% | −13% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| INBS | 17% | 33% | 33% | 33% | 50% | 27% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| INBS | −85% | −89% | −99% | −84% | −85% | −92% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since December 23, 2020: 100% from December 23, 2020 to October 15, 2026. Getting back needed a 1836567% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 19, 2026 | −17.7% | −0.6% | −29.8% | −39.4% |
| May 14, 2026 | +0.5% | −0.4% | −34.1% | −41.6% |
| February 12, 2026 | −4.4% | −1.5% | −13.1% | −26.5% |
| February 5, 2026 | −10.4% | +0.6% | −29.5% | −41.0% |
| November 12, 2025 | −11.2% | −1.6% | −15.1% | −30.6% |
| November 7, 2025 | +0.5% | +1.7% | −7.8% | −5.2% |
| August 15, 2025 | +1.4% | −0.3% | 0.0% | +27.0% |
| August 7, 2025 | −2.6% | +0.7% | −5.1% | +5.4% |
| May 13, 2025 | +5.3% | +0.8% | +4.9% | +55.7% |
| February 13, 2025 | +2.4% | +1.1% | −11.2% | −15.7% |
| February 10, 2025 | −1.9% | +0.8% | +17.0% | +3.8% |
| February 6, 2025 | +24.7% | −0.6% | +39.4% | +30.6% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY24 Q1 | $2.2M |
| FY24 Q2 | $2.7M |
| FY24 Q3 | $3.2M |
| FY24 Q4 | $3.1M |
| FY25 Q1 | $3.2M |
| FY25 Q2 | $3M |
| FY25 Q3 | $3M |
| FY25 Q4 | $3.1M |
| FY26 Q1 | $3.2M |
| FY26 Q2 | $3.3M |
| FY26 Q3 | $3.5M |
| FY26 Q4 | $4.2M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY24 Q1 | 189.0% |
| FY24 Q2 | 193.7% |
| FY24 Q3 | 166.3% |
| FY24 Q4 | 98.4% |
| FY25 Q1 | 48.1% |
| FY25 Q2 | 11.2% |
| FY25 Q3 | -4.8% |
| FY25 Q4 | -1.9% |
| FY26 Q1 | -1.2% |
| FY26 Q2 | 9.7% |
| FY26 Q3 | 15.1% |
| FY26 Q4 | 38.1% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY24 Q1 | -642.8% |
| FY24 Q2 | -505.4% |
| FY24 Q3 | -320.5% |
| FY24 Q4 | -330.5% |
| FY25 Q1 | -327.1% |
| FY25 Q2 | -355.2% |
| FY25 Q3 | -342.8% |
| FY25 Q4 | -349.1% |
| FY26 Q1 | -345.3% |
| FY26 Q2 | -340.3% |
| FY26 Q3 | -335.9% |
| FY26 Q4 | -297.8% |
| Fiscal year | 2020 Jun 2020 | 2021 Jun 2021 | 2022 Jun 2022 | 2023 Jun 2023 | 2024 Jun 2024 | 2025 Jun 2025 | 2026 Jun 2026 |
|---|---|---|---|---|---|---|---|
| Income | |||||||
| Revenue | 0 | 2 | 0 | 1 | 3 | 3 | 4 |
| Gross profit | — | — | — | 0 | 1 | 1 | 2 |
| EBITDA | — | — | −8 | −12 | −9 | −10 | −11 |
| Operating income | −3 | −6 | −8 | −13 | −10 | −11 | −13 |
| Net income | −3 | −7 | −8 | −11 | −10 | −11 | −12 |
| Diluted EPS | −$0.06 | −$24.48 | −$20.39 | −$19.05 | −$19.14 | −$20.04 | −$8.44 |
| Growth (year on year) | |||||||
| Revenue | — | +949.3% | −77.9% | +187.5% | +147.6% | −1.9% | +38.1% |
| Margins | |||||||
| Gross margin | — | — | — | 26.0% | 45.8% | 40.8% | 48.6% |
| EBITDA margin | — | — | <−999% | −937.3% | −299.1% | −318.1% | −271.5% |
| Operating margin | <−999% | −281.4% | <−999% | <−999% | −330.5% | −349.8% | −299.1% |
| Net margin | <−999% | −355.3% | <−999% | −845.9% | −326.4% | −346.2% | −294.9% |
| Free-cash-flow margin | — | — | — | — | −314.7% | −324.6% | −285.9% |
| Cash flow | |||||||
| Cash from operations | −0 | −11 | −3 | −7 | −10 | −10 | −12 |
| Capital spending | — | — | — | — | 0 | 0 | 0 |
| Free cash flow | — | — | — | — | −10 | −10 | −12 |
| Stock-based pay | — | — | — | 0 | 0 | 0 | 0 |
| Free cash flow after stock pay | — | — | — | — | −10 | −10 | −12 |
| Balance sheet | |||||||
| Cash | 0 | 13 | 8 | 2 | 6 | 1 | 4 |
| Total debt | 5 | 0 | 0 | 1 | 1 | 0 | 0 |
| Net debt (negative = net cash) | 5 | −13 | −8 | −1 | −6 | −1 | −4 |
| Diluted shares | — | — | — | — | — | — | 1m |
| Quarter | 2025 Q1 Sept 2024 | 2025 Q2 Dec 2024 | 2025 Q3 Mar 2025 | 2025 Q4 Jun 2025 | 2026 Q1 Sept 2025 | 2026 Q2 Dec 2025 | 2026 Q3 Mar 2026 | 2026 Q4 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 998 | 741 | 902 | 411 | 1,112 | 897 | 1,061 | 1,146 |
| Gross profit | 347 | 223 | 341 | 336 | 518 | 460 | 535 | 537 |
| EBITDA | −2,484 | −1,959 | −2,258 | −2,862 | −2,742 | −2,354 | −2,657 | −3,681 |
| Operating income | −2,725 | −2,264 | −2,560 | −3,106 | −3,000 | −2,636 | −2,947 | −3,969 |
| Net income | −2,686 | −2,249 | −2,544 | −3,090 | −2,983 | −2,678 | −2,863 | −3,908 |
| Diluted EPS | −$7.00 | −$4.96 | −$4.41 | −$4.12 | −$3.50 | −$2.82 | −$1.80 | −$0.90 |
| Growth (year on year) | ||||||||
| Revenue | +10.2% | −19.2% | −0.6% | +7.9% | +11.4% | +21.0% | +17.6% | +178.9% |
| Margins | ||||||||
| Gross margin | 34.7% | 30.1% | 37.8% | 81.7% | 46.6% | 51.3% | 50.5% | 46.8% |
| EBITDA margin | −248.8% | −264.4% | −250.3% | −696.7% | −246.6% | −262.5% | −250.4% | −321.2% |
| Operating margin | −273.0% | −305.5% | −283.8% | −756.1% | −269.8% | −293.9% | −277.8% | −346.4% |
| Net margin | −269.0% | −303.5% | −281.9% | −752.1% | −268.3% | −298.6% | −269.9% | −341.0% |
| Free-cash-flow margin | — | — | — | — | −262.4% | −182.4% | −407.0% | −277.7% |
| Cash flow | ||||||||
| Cash from operations | −2,387 | −2,325 | −2,755 | −2,210 | −2,847 | −1,568 | −4,331 | −3,182 |
| Capital spending | — | — | — | — | 70 | 68 | −13 | 0 |
| Free cash flow | — | — | — | — | −2,917 | −1,636 | −4,318 | −3,182 |
| Stock-based pay | 202 | 12 | 0 | 12 | 12 | 62 | 12 | 97 |
| Free cash flow after stock pay | — | — | — | — | −2,929 | −1,697 | −4,330 | −3,280 |
| Last 12 months unless stated | INBS | CNSY | BMRA | MCTA | ICCM | NRXS | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $4m | $4m | $4m | $5m | $3m | $5m | $99m |
| Revenue growth, last 12 months | 38.1% | −21.0% | −11.2% | −22.7% | 2.7% | 65.2% | 9.2% |
| Revenue growth, 3-year average | 39.0% | 16.1% | −7.1% | — | — | 25.6% | 13.5% |
| Revenue growth, latest quarter | 178.9% | −70.4% | −8.3% | — | — | 115.7% | 10.2% |
| Gross margin | 48.6% | 15.1% | 0.9% | 99.3% | 36.3% | 85.6% | 61.2% |
| Operating margin | −297.8% | −628.1% | −125.2% | −0.6% | −446.7% | −144.5% | −8.5% |
| Operating margin, 3-year average | −325.8% | −383.3% | −114.4% | — | — | −249.7% | −17.9% |
| Net margin | −294.9% | −620.7% | −115.5% | −0.5% | −445.6% | −144.4% | −12.0% |
| Cash from operations / revenue | −283.0% | −527.6% | −91.2% | −25.3% | −431.3% | −105.7% | −1.9% |
| Free-cash-flow margin | −285.9% | −560.3% | −91.2% | −32.4% | −432.4% | −105.7% | −3.9% |
| Free-cash-flow margin, 3-year average | — | −402.6% | −79.7% | — | — | −224.0% | −7.0% |
| Stock pay / revenue | 4.3% | 73.6% | 8.2% | — | 40.6% | 9.2% | 6.1% |
| Change in share count | 50.1% | −99.4% | 26.7% | 5.3% | 25.0% | 43.8% | 4.0% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 38.1% | 9.1% | 20 of 129 |
| Change in growth rate Growth | +22.9pp | -0.6pp | 7 of 129 |
| Gross margin Profitability | 48.6% | 61.9% | 88 of 123 |
| Operating margin Profitability | -297.8% | -8.3% | 112 of 132 |
| Net margin Profitability | -294.9% | -12.0% | 113 of 133 |
| Free-cash-flow margin Cash generation | -285.9% | -3.4% | 112 of 128 |
| Stock pay as % of revenue Cash generation | 4.3% | 6.1% | 55 of 123 |
| Days sales outstanding Balance sheet | 73 days | 57 days | 88 of 118 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Sales of Goods Cartidges | $2.5M | 59.0% | ▲ 41.1% |
| Sales of Goods Readers | $902,263 | 21.4% | ▲ 26.8% |
| Other Sales Accessories | $827,349 | 19.6% | ▲ 43.0% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United Kingdom | $4.2M | 98.5% | ▲ 44.8% |
| Other Country | $40,199 | 1.0% | ▼ 69.7% |
| Asia Pacific | $12,467 | 0.3% | ▼ 57.3% |
| Americas | $8,750 | 0.2% | ▼ 61.3% |
From Intelligent BIO Solutions Inc.'s 10-K filed August 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Armistice Capital, LLC | $324,506 | 141K | 78.0% | ▲ 8.8% |
| Geode Capital Management, LLC | $47,827 | 21K | 11.5% | ▼ 27.2% |
| Vanguard Capital Management LLC | $13,334 | 6K | 3.2% | 0.0% |
| UBS Group AG | $13,162 | 6K | 3.2% | ▲ 1441.7% |
| Vanguard Fiduciary Trust Co | $9,084 | 4K | 2.2% | 0.0% |
| Tower Research Capital LLC (TRC) | $7,528 | 3K | 1.8% | ▲ 162.4% |
| Osaic Holdings, Inc. | $460 | 0K | 0.1% | 0.0% |
| Barclays PLC | $326 | 0K | 0.1% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Intelligent BIO Solutions Inc.'s complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
